AutoIVF
Natick, US · Founded 2019 · Delaware corporation · 11 employees on LinkedIn · 2 known investors
AutoIVF builds chip-based microfluidic systems that automate embryology steps in IVF laboratories, including its OvaReady product for oocyte preparation using a software-controlled instrument and single-use microfluidic kit. It targets IVF clinics and fertility labs, aiming to reduce operator variability and standardize laboratory workflows.
Also known as AutoIVF Inc. · AutoIVF, Inc.
Founders & leadership
AutoIVF was founded in 2019 by Thomas Toth and Thomas L. Toth.
Board
Investors · 2
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$8.6M disclosed across 3 of 4 rounds · 2020–2025
▶$5MraisedMay 2025 · 24 investors · BiotechnologyRule 506(b)
- Erin SchardtDirector
- Mitchel SayareExecutive Officer, Director
- Ravi KapurExecutive Officer, Director
- Michael AlperDirector
- David SableDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedJun 2023 · 15 investors · BiotechnologyRule 506(b)
- Ravi KapurExecutive Officer, Director
- Mehmet TonerDirector
- Alan PenziasDirector
- Dionisios SakkasDirector
- Mitchel SayareExecutive Officer, Director
- Thomas TothDirector
- Michael AlperDirector
- Offering amount
- $4.9M
- Amount sold
- $2.6M
- Minimum investment
- $5K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1MraisedMar 2020 · 8 investors · BiotechnologyRule 506(b)
- Thomas TothExecutive Officer, Director
- Mitchell SayareExecutive Officer, Director
- Denny SakkasDirector
- Mehmet TonerDirector
- Michael AlperDirector
- Ravi KapurDirector
- Offering amount
- $2M
- Amount sold
- $1M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026AutoIVF, Inc. is a fertility technology company that applies chip-based microfluidic systems to automate critical embryology steps in in vitro fertilization (IVF) laboratories. Its stated approach is to reduce manual variability while preserving established clinical decision-making, with systems designed to integrate into existing IVF laboratories and to improve reproducibility and workflow stability in real-world clinical use.
The company's flagship technology is OvaReady, which pairs a software-controlled instrument with a sterile, single-use microfluidic kit to standardize oocyte preparation. The system processes follicular fluid in a closed, controlled workflow with samples contained in the disposable, and is designed to produce denuded oocytes suitable for cryopreservation or intracytoplasmic sperm injection (ICSI), with the goal of eliminating operator variability. According to a third-party funding record, the OvaReady system is also positioned to enable fertility services to be delivered outside traditional IVF labs. The company is headquartered at 22 Strathmore Road, Suite 317, Natick, Massachusetts.
Traction
Publication of the underlying microfluidic oocyte recovery technology in Nature Medicine (February 12, 2026) and completion of a funding round led by Vitrolife Group in May 2025, intended to support expansion of operations and development efforts.
Latest developments
In February 2026, Nature Medicine published research on microfluidic automation improving oocyte recovery from follicular fluid in IVF patients, the technology behind OvaReady. The company is hiring, with an open research engineer position listed on its careers page.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
AutoIVF operates in the automated fertility care and IVF laboratory equipment segment. Its May 2025 round was led by Vitrolife Group, an established company in the fertility products sector.
Technology
AutoIVF's technology is based on microfluidic chips that automate embryology steps. The OvaReady product combines a software-controlled instrument with a sterile, single-use microfluidic kit; follicular fluid is processed in a closed, controlled workflow with the sample contained in the disposable, yielding denuded oocytes suitable for cryopreservation or ICSI. The underlying method was published in Nature Medicine on February 12, 2026, in a paper on microfluidic automation improving oocyte recovery from follicular fluid of IVF patients.
Go-to-market
IVF laboratories and fertility clinics, with the products designed to integrate into existing laboratory workflows; a third-party profile also describes the technology as enabling fertility services outside traditional IVF labs.
Geography
Headquartered in Natick, Massachusetts, United States.
History
AutoIVF's OvaReady system builds on microfluidic oocyte recovery technology later published in Nature Medicine in February 2026. In May 2025 the company raised an undisclosed funding round led by Vitrolife Group, with new investors including Alpha Edison, to expand operations and development.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 1
by search overlapCompanies competing with AutoIVF for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsNature Medicine published a paper titled "Microfluidic automation improves oocyte recovery from follicular fluid of patients undergoing in vitro fertilization," the technology underlying AutoIVF's OvaReady system.
AutoIVF Inc., based in Natick, MA, raised an undisclosed amount in a round led by Vitrolife Group with participation from new investors including Alpha Edison. The company said it intended to expand operations and development efforts.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 5
primary sources listed
- AutoIVFautoivf.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does AutoIVF do?
- AutoIVF develops chip-based microfluidic automation for IVF laboratory workflows, led by its OvaReady oocyte preparation system.
- Who founded AutoIVF?
- AutoIVF was founded by Thomas Toth, Thomas L. Toth in 2019.
- Who are AutoIVF's investors?
- AutoIVF's investors include Alpha Edison.
- How much funding has AutoIVF raised?
- AutoIVF has disclosed $8.6M raised across 3 of its 4 known rounds.
- Where is AutoIVF headquartered?
- AutoIVF is headquartered in Natick, US.